Nuvectis Pharma Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Public

  • Employees
  • 13

Employees

  • Stock Symbol
  • NVCT

Stock Symbol

  • Share Price
  • $19.39
  • (As of Friday Closing)

Nuvectis Pharma General Information

Description

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1 Bridge Plaza, 2nd Floor
  • Suite 275
  • Fort Lee, NJ 07024
  • United States
+1 (360)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1 Bridge Plaza, 2nd Floor
  • Suite 275
  • Fort Lee, NJ 07024
  • United States
+1 (360)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nuvectis Pharma Stock Performance

As of 20-Nov-2026, Nuvectis Pharma’s stock price is $19.39. Its current market cap is $667M with 34.4M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$19.39 $19.84 $5.77 - $29.27 $667M 34.4M 206K -$2.00

Nuvectis Pharma Financials Summary

As of 30-Sep-2026, Nuvectis Pharma has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 667,283 157,950 87,357 122,445
Revenue 0 0 0 0
EBITDA (52,123) (27,574) (19,847) (22,897)
Net Income (50,454) (26,442) (19,000) (22,260)
Total Assets 140,839 31,709 18,607 19,185
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Nuvectis Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Nuvectis Pharma‘s full profile, request access.

Request a free trial

Nuvectis Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Nuvectis Pharma‘s full profile, request access.

Request a free trial

Nuvectis Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for
Drug Discovery
Fort Lee, NJ
13 As of 2025

Seattle, WA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nuvectis Pharma Competitors (6)

One of Nuvectis Pharma’s 6 competitors is CTI BioPharma, a Formerly VC-backed company based in Seattle, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CTI BioPharma Formerly VC-backed Seattle, WA
Sutro Biopharma Formerly VC-backed South San Francisco, CA
ADC Therapeutics Formerly VC-backed Epalinges, Switzerland
Ability Pharma Private Equity-Backed Cerdanyola, Spain
OncoResponse Venture Capital-Backed Houston, TX
To view Nuvectis Pharma’s complete competitors history, request access »

Nuvectis Pharma Patents

Nuvectis Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026226638-A1 Methods of treating cancer using src kinase inhibitors Pending 23-Apr-2025
EP-4805354-A1 Crystalline forms of the tyrosine kinase inhibitor ecf506 Pending 08-Nov-2023
WO-2025101861-A1 Crystalline forms of the tyrosine kinase inhibitor ecf506 Inactive 08-Nov-2023
EP-4805355-A1 Crystalline salt forms of the tyrosine kinase inhibitor ecf506 Pending 08-Nov-2023
WO-2025101874-A1 Crystalline salt forms of the tyrosine kinase inhibitor ecf506 Inactive 08-Nov-2023 C07D487/04
To view Nuvectis Pharma’s complete patent history, request access »

Nuvectis Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nuvectis Pharma ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

30.07 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Nuvectis Pharma’s complete esg history, request access »

Nuvectis Pharma FAQs

  • When was Nuvectis Pharma founded?

    Nuvectis Pharma was founded in 2020.

  • Where is Nuvectis Pharma headquartered?

    Nuvectis Pharma is headquartered in Fort Lee, NJ.

  • What is the size of Nuvectis Pharma?

    Nuvectis Pharma has 13 total employees.

  • What industry is Nuvectis Pharma in?

    Nuvectis Pharma’s primary industry is Drug Discovery.

  • Is Nuvectis Pharma a private or public company?

    Nuvectis Pharma is a Public company.

  • What is Nuvectis Pharma’s stock symbol?

    The ticker symbol for Nuvectis Pharma is NVCT.

  • What is the current stock price of Nuvectis Pharma?

    As of 20-Nov-2026 the stock price of Nuvectis Pharma is $19.39.

  • What is the current market cap of Nuvectis Pharma?

    The current market capitalization of Nuvectis Pharma is $667M.

  • Who are Nuvectis Pharma’s competitors?

    CTI BioPharma, Sutro Biopharma, ADC Therapeutics, Ability Pharma, and OncoResponse are some of the 6 competitors of Nuvectis Pharma.

  • What is Nuvectis Pharma’s annual earnings per share (EPS)?

    Nuvectis Pharma’s EPS for 12 months was -$2.00.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process